Olema, Novartis and metastatic breast cancer
Olema Pharmaceuticals (OLMA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Sam ...
US biopharma Olema Pharmaceuticals has announced a clinical trial collaboration and supply agreement with Swiss pharma giant ...
Olema Pharmaceuticals, Inc. (“Olema” or “”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast ...
Bohen, M.D., Ph.D., President and Chief Executive Officer of Olema Oncology. “At ENA 2024, we presented three new, robust preclinical data sets. Palazestrant demonstrated combinability and ...
Olema Pharmaceuticals, Inc. (NASDAQ:OLMA – Get Free Report)’s share price gapped up prior to trading on Friday .The stock had previously closed at $7.87, but opened at $8.21. Olema ...
Live webcasts of the presentations and any accompanying materials will be available under the News & Events section of Olema’s investor relations website at ir.olema.com. The webcasts will be ...
A copy of the poster will be made available on the Publications page of Olema’s website in alignment with the Symposium’s embargo policy. Olema will hold a conference call to discuss these ...
Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s ...
Novartis will make an upfront payment of $1.0 billion to PTCT and the latter will also be eligible for up to $1.9 billion in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback